NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure

被引:126
作者
Bourajjaj, Meriem [2 ,3 ]
Armand, Anne-Sophie [2 ,3 ]
Martins, Paula A. da Costa [2 ,3 ]
Weijts, Bart [2 ,3 ]
van der Nagel, Roel [2 ,3 ]
Heeneman, Sylvia [4 ]
Wehrens, Xander H. [5 ]
De Windt, Leon J. [1 ,2 ,3 ]
机构
[1] Univ Utrecht, Med Ctr, Div Heart & Lungs, Dept Med Physiol, NL-3584 CM Utrecht, Netherlands
[2] Royal Netherlands Acad Sci, Hubrecht Inst, NL-3584 CT Utrecht, Netherlands
[3] Royal Netherlands Acad Sci, Interuniv Cardiol Inst Netherlands, NL-3584 CT Utrecht, Netherlands
[4] Univ Hosp Maastricht, Dept Pathol, NL-6229 HX Maastricht, Netherlands
[5] Baylor Coll Med, Houston, TX 77030 USA
关键词
D O I
10.1074/jbc.M801296200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
One major intracellular signaling pathway involved in heart failure employs the phosphatase calcineurin and its downstream transcriptional effector nuclear factor of activated T-cells ( NFAT). In vivo evidence for the involvement ofNFATfactors in heart failure development is still ill defined. Here we reveal that nfatc2 transcripts outnumber those from other nfat genes in the unstimulated heart by severalfold. Transgenic mice with activated calcineurin in the postnatal myocardium crossbred with nfatc2-null mice revealed a significant abrogation of calcineurin-provoked cardiac growth, indicating that NFATc2 plays an important role downstream of calcineurin and validates the original hypothesis that calcineurin mediates myocyte hypertrophy through activation of NFAT transcription factors. In the absence of NFATc2, a clear protection against the geometrical, functional, and molecular deterioration of the myocardium following biomechanical stress was also evident. In contrast, physiological cardiac enlargement in response to voluntary exercise training was not affected in nfatc2-null mice. Combined, these results reveal a major role for the NFATc2 transcription factor in pathological cardiac remodeling and heart failure.
引用
收藏
页码:22295 / 22303
页数:9
相关论文
共 34 条
[1]   Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo [J].
Antos, CL ;
McKinsey, TA ;
Frey, N ;
Kutschke, W ;
McAnally, J ;
Shelton, JM ;
Richardson, JA ;
Hill, JA ;
Olson, EN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) :907-912
[2]   Autoamplification of NFATc1 expression determines its essential role in bone homeostasis [J].
Asagiri, M ;
Sato, K ;
Usami, T ;
Ochi, S ;
Nishina, H ;
Yoshida, H ;
Morita, I ;
Wagner, EF ;
Mak, TW ;
Serfling, E ;
Takayanagi, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (09) :1261-1269
[3]   Impaired cardiac hypertrophic response in calcineurin Aβ-deficient mice [J].
Bueno, OF ;
Wilkins, BJ ;
Tymitz, KM ;
Glascock, BJ ;
Kimball, TF ;
Lorenz, JN ;
Molkentin, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (07) :4586-4591
[4]   The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy [J].
Buitrago, M ;
Lorenz, K ;
Maass, AH ;
Maass, SO ;
Keller, U ;
Schmitteckert, EM ;
Ivashchenko, Y ;
Lohse, MJ ;
Engelhardt, S .
NATURE MEDICINE, 2005, 11 (08) :837-844
[5]  
Chuvpilo S, 1999, J IMMUNOL, V162, P7294
[6]   Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo - An apoptosis-independent model of dilated heart failure [J].
De Windt, LJ ;
Lim, HW ;
Taigen, T ;
Wencker, D ;
Condorelli, G ;
Dorn, GW ;
Kitsis, RN ;
Molkentin, JD .
CIRCULATION RESEARCH, 2000, 86 (03) :255-263
[7]   Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo [J].
De Windt, LJ ;
Lim, HW ;
Bueno, OF ;
Liang, QR ;
Delling, U ;
Braz, JC ;
Glascock, BJ ;
Kimball, TF ;
del Monte, F ;
Hajjar, RJ ;
Molkentin, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (06) :3322-3327
[8]   Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress [J].
Esposito, G ;
Rapacciuolo, A ;
Prasad, SVN ;
Takaoka, H ;
Thomas, SA ;
Koch, WJ ;
Rockman, HA .
CIRCULATION, 2002, 105 (01) :85-92
[9]   Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy - Preservation of systolic function [J].
Hill, JA ;
Rothermel, B ;
Yoo, KD ;
Cabuay, B ;
Demetroulis, E ;
Weiss, RM ;
Kutschke, W ;
Bassel-Duby, R ;
Williams, RS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (12) :10251-10255
[10]  
HO KKL, 1993, J AM COLL CARDIOL S, V22, P6